Thyroid autoimmunity and ophthalmopathy related to melanoma biological therapy

European Journal of Endocrinology

Volumn 164, Issue 2, 2011, Pages 303-307

  Min, Le ^a   Vaidya, Anand ^a   Becker, Carolyn ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BEVACIZUMAB; FLUORODEOXYGLUCOSE F 18; IPILIMUMAB; METHYLPREDNISOLONE; METHYLPREDNISOLONE SODIUM SUCCINATE; PREDNISONE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GLUCOCORTICOID; THYROID ANTIBODY; THYROTROPIN; THYROTROPIN RECEPTOR ANTIBODY; THYROXINE; TUMOR CELL VACCINE;

ADULT; ARTICLE; CASE REPORT; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DRUG MEGADOSE; DRUG WITHDRAWAL; ENDOCRINE OPHTHALMOPATHY; FEMALE; HUMAN; LABORATORY TEST; MALE; MELANOMA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; THYROIDITIS; TREATMENT RESPONSE; ADVANCED CANCER; ANTIBODY TITER; AUTOIMMUNITY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CONJUNCTIVITIS; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE REDUCTION; EUTHYROIDISM; EXOPHTHALMOS; EYE PAIN; INTRAOCULAR PRESSURE; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT MONITORING; PERIORBITAL EDEMA; PHYSICAL EXAMINATION; THYROID FUNCTION TEST; TREATMENT DURATION;

ADULT; ANTIBODIES, MONOCLONAL; FEMALE; GRAVES OPHTHALMOPATHY; HUMANS; MALE; MELANOMA; MIDDLE AGED; SKIN NEOPLASMS; THYROIDITIS, AUTOIMMUNE;

EID: 78751559991     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-10-0833     Document Type: Article

References (23)

1. Chambers CA, Kuhns MS, Egen JG & Allison JP. CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy. Annual Review of Immunology 2001 19 565-594. (doi:10.1146/annurev.immunol.19.1.565)
2. Blansfield JA, Beck KE, Tran K, Yang JC, Hughes MS, Kammula US, Royal RE, Topalian SL, Haworth LR, Levy C, Rosenberg SA & Sherry RM. Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer. Journal of Immunotherapy 2005 28 593-598. (doi:10.1097/01.cji.0000178913.41256.06)
3. Dillard T, Yedinak CG, Alumkal J & Fleseriu M. Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: serious immune related adverse events across a spectrumof cancer subtypes. Pituitary 2010 13 29-38. (doi:10.1007/s11102-009-0193-z)
4. Boehm S, Rothermundt C, Hess D & Joerger M. Antiangiogenic drugs in oncology: a focus on drug safety and the elderly - a mini-review. Gerontology 2010 56 303-309. (doi:10.1159/000262450)
5. Karantanis D, Bogsrud TV, Wiseman GA, Mullan BP, Subramaniam RM, Nathan MA, Peller PJ, Bahn RS & Lowe VJ. Clinical significance of diffusely increased 18F-FDG uptake in the thyroid gland. Journal of Nuclear Medicine 2007 48 896-901. (doi:10.2967/jnumed.106.039024)
6. Yasuda S, Shohtsu A, Ide M, Takagi S, Takahashi W, Suzuki Y & Horiuchi M. Chronic thyroiditis: diffuse uptake of FDG at PET. Radiology 1998 207 775-778.
7. Liu Y. Clinical significance of thyroid uptake on F18-fluorodeoxyglucose positron emission tomography. Annals of Nuclear Medicine 2009 23 17-23. (doi:10.1007/s12149-008-0198-0)
8. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbe C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A & Urba WJ. Improved survival with ipilimumab in patients with metastatic melanoma. New England Journal of Medicine 2010 363 711-723. (doi:10.1056/ NEJMoa1003466)
9. Attia P, Phan GQ, Maker AV, Robinson MR, Quezado MM, Yang JC, Sherry RM, Topalian SL, Kammula US, Royal RE, Restifo NP, Haworth LR, Levy C, Mavroukakis SA, Nichol G, Yellin MJ & Rosenberg SA. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. Journal of Clinical Oncology 2005 23 6043-6053. (doi:10.1200/JCO.2005.06.205)
10. Beck KE, Blansfield JA, Tran KQ, Feldman AL, Hughes MS, Royal RE, Kammula US, Topalian SL, Sherry RM, Kleiner D, Quezado M, Lowy I, Yellin M, Rosenberg SA & Yang JC. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. Journal of Clinical Oncology 2006 24 2283-2289. (doi:10.1200/JCO.2005.04.5716)
11. Sanderson K, Scotland R, Lee P, Liu D, Groshen S, Snively J, Sian S, Nichol G, Davis T, Keler T, Yellin M & Weber J. Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma. Journal of Clinical Oncology 2005 23 741-750. (doi:10.1200/JCO.2005.01.128)
12. Weber J, Thompson JA, Hamid O, Minor D, Amin A, Ron I, Ridolfi R, Assi H, Maraveyas A, Berman D, Siegel J & O'Day SJ. A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresecTable stage III or IV melanoma. Clinical Cancer Research 2009 15 5591-5598. (doi:10.1158/1078-0432.CCR-09-1024)
13. Bahn RS. Graves' ophthalmopathy. New England Journal of Medicine 2010 362 726-738. (doi:10.1056/NEJMra0905750)
14. Ueda H, Howson JM, Esposito L, Heward J, Snook H, Chamberlain G, Rainbow DB, Hunter KM, Smith AN, Di Genova G, Herr MH, Dahlman I, Payne F, Smyth D, Lowe C, Twells RC, Howlett S, Healy B, Nutland S, Rance HE, Everett V, Smink LJ, Lam AC, Cordell HJ, Walker NM, Bordin C, Hulme J, Motzo C, Cucca F, Hess JF, Metzker ML, Rogers J, Gregory S, Allahabadia A, Nithiyananthan R, Tuomilehto-Wolf E, Tuomilehto J, Bingley P, Gillespie KM, Undlien DE, Ronningen KS, Guja C, Ionescu-Tirgoviste C, Savage DA, Maxwell AP, Carson DJ, Patterson CC, Franklyn JA, Clayton DG, Peterson LB, Wicker LS, Todd JA & Gough SC. Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature 2003 423 506-511. (doi:10.1038/nature01621)
15. Chistiakov DA & Turakulov RI. CTLA-4 and its role in autoimmune thyroid disease. Journal of Molecular Endocrinology 2003 31 21-36. (doi:10.1677/jme.0.0310021)
16. Kavvoura FK, Akamizu T, Awata T, Ban Y, Chistiakov DA, Frydecka I, Ghaderi A, Gough SC, Hiromatsu Y, Ploski R, Wang PW, Bednarczuk T, Chistiakova EI, Chojm M, Heward JM, Hiratani H, Juo SH, Karabon L, Katayama S, Kurihara S, Liu RT, Miyake I, Omrani GH, Pawlak E, Taniyama M, Tozaki T & Ioannidis JP. Cytotoxic T-lymphocyte associated antigen 4 gene polymorphisms and autoimmune thyroid disease: a meta-analysis. Journal of Clinical Endocrinology and Metabolism 2007 92 3162-3170. (doi:10.1210/jc.2007-0147)
17. Vaidya B, Imrie H, Perros P, Dickinson J, McCarthy MI, Kendall-Taylor P & Pearce SH. Cytotoxic T lymphocyte antigen-4 (CTLA-4) gene polymorphism confers susceptibility to thyroid associated orbitopathy. Lancet 1999 354 743-744. (doi:10.1016/S0140-6736(99)01465-8) (Pubitemid 29405794)
18. Vaidya B, Oakes EJ, Imrie H, Dickinson AJ, Perros P, Kendall-Taylor P & Pearce SH. CTLA4 gene and Graves' disease: association of Graves' diseasewith the CTLA4 exon 1 and intron 1 polymorphisms, but not with the promoter polymorphism. Clinical Endocrinology 2003 58 732-735. (doi:10.1046/j.1365-2265.2003.01778.x)
19. Bednarczuk T, Gopinath B, Ploski R &Wall JR. Susceptibility genes in Graves' ophthalmopathy: searching for a needle in a haystack? Clinical Endocrinology 2007 67 3-19. (doi:10.1111/j.1365-2265.2007.02854.x)
20. Han S, Zhang S, Zhang W, Li R, Li Y, Wang Z, Xie Y & Mao Y. CTLA4 polymorphisms and ophthalmopathy in Graves' disease patients: association study and meta-analysis. Human Immunology 2006 67 618-626. (doi:10.1016/j.humimm.2006. 05.003)
21. Downey SG, Klapper JA, Smith FO, Yang JC, Sherry RM, Royal RE, Kammula US, Hughes MS, Allen TE, Levy CL, Yellin M, Nichol G, White DE, Steinberg SM & Rosenberg SA. Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. Clinical Cancer Research 2007 13 6681-6688. (doi:10.1158/1078-0432.CCR-07-0187)
22. Reismuller B, Azizi AA, Peyrl A, Heinrich M, Gruber-Olipitz M, Luckner D, Rothschild KV & Slavc I. Feasibility and tolerability of bevacizumab in children with primary CNS tumors. Pediatric Blood and Cancer 2010 54 681-686. (doi:10.1002/pbc.22409)
23. Kamba T, Tam BY, Hashizume H, Haskell A, Sennino B, Mancuso MR, Norberg SM, O'Brien SM, Davis RB, Gowen LC, Anderson KD, Thurston G, Joho S, Springer ML, Kuo CJ & McDonald DM. VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature. American Journal of Physiology. Heart and Circulatory Physiology 2006 290 H560-H576. (doi:10.1152/ajpheart.00133.2005)